{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000093","form_type":"8-K/A","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.582533+00:00","generated_at":"2026-06-13T08:12:51.466063+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Caribou announces positive long-term follow-up from ANTLER Phase 1 of CB-010","bullets":["Positive long-term follow-up results from dose escalation portion of ANTLER Phase 1 trial.","CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for relapsed/refractory B-NHL.","Results announced July 13, 2023; this 8-K/A corrects an XBRL date error on the cover page."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000093","json":"https://secwatch.observer/filing/0001619856-23-000093.json","markdown":"https://secwatch.observer/filing/0001619856-23-000093.md","text":"https://secwatch.observer/filing/0001619856-23-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000093/0001619856-23-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000093/crbu-20230713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:12:51.466063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}